SCHEMBL2329966

SCHEMBL2329966

O=c1cc(O)c(-c2ccccc2)c(Cl)[nH]1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HTT P42858 2/20 1.00
L3MBTL1 Q9Y468 1/20 0.69
MEN1 O00255 2/20 0.65
KMT2A Q03164 2/20 0.65
MAPT P10636 2/20 0.63
TYMP P19971 1/20 0.53
KDM4E B2RXH2 3/20 0.46
ALDH1A1 P00352 1/20 0.46
GRIN2D O15399 1/20 0.43
GRIN3B O60391 1/20 0.43
GRIN1 Q05586 1/20 0.43
GRIN2A Q12879 1/20 0.43
GRIN2B Q13224 1/20 0.43
GRIN2C Q14957 1/20 0.43
GRIN3A Q8TCU5 1/20 0.43
GPR84 Q9NQS5 2/20 0.43
FASN P49327 1/20 0.43
RXFP1 Q9HBX9 1/20 0.42
GPR35 Q9HC97 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2897732 0.72 HTT (0.55) HTTL3MBTL1KDM4EALDH1A1RXFP1
SCHEMBL2333736 0.68 L3MBTL1 (0.57) HTTL3MBTL1MEN1KMT2AMAPT
SCHEMBL8783774 0.67 FASN (0.74) MEN1KMT2AMAPTKDM4EGRIN2D
Hydrochloric Acid SCHEMBL6095500 0.67 L3MBTL1 (0.56) HTTL3MBTL1MEN1KMT2AMAPT
SCHEMBL16382638 0.67 HTT (0.50) HTTMAPTKDM4EALDH1A1GPR84
SCHEMBL11374087 0.67 HTT (0.50) HTTMEN1KMT2AMAPTTYMP
SCHEMBL29995337 0.67 HTT (0.50) HTTMEN1KMT2AKDM4EALDH1A1
SCHEMBL9724160 0.67 KDM4E (0.64) HTTMEN1KMT2AKDM4EALDH1A1
SCHEMBL28583369 0.66 NQO1 (0.59) HTTMEN1KMT2AMAPTKDM4E
SCHEMBL31545354 0.66 ALOX5 (0.58) HTTMEN1KMT2AMAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8513424-B2 Pyridone GPR119 G protein-coupled receptor agonists BRISTOL-MYERS SQUIBB COMPANY (US) 2013-08-20 US disclosed
US-20120258959-A1 PYRIDONE GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS BRISTOL-MYERS SQUIBB COMPANY 2012-10-11 US disclosed
US-8232404-B2 Pyridone GPR119 G protein-coupled receptor agonists BRISTOL-MYERS SQUIBB COMPANY (US) 2012-07-31 US disclosed
US-20110245227-A1 PYRIDONE GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS BRISTOL-MYERS SQUIBB COMPANY 2011-10-06 US disclosed
EP-2170864-B1 PYRIDONE GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS BRISTOL MYERS SQUIBB CO (US) 2011-09-14 EP disclosed
US-8003796-B2 Pyridone GPR119 G protein-coupled receptor agonists BRISTOL-MYERS SQUIBB COMPANY (US) 2011-08-23 US disclosed
EP-2170864-A1 PYRIDONE GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS Bristol-Myers Squibb Company (US) 2010-04-07 EP disclosed
US-20090023702-A1 PYRIDONE GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS BRISTOL-MYERS SQUIBB COMPANY 2009-01-22 US disclosed
WO-2009012275-A1 PYRIDONE GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS BRISTOL-MYERS SQUIBB COMPANY (US) 2009-01-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120258959-A1 PYRIDONE GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS GPR119, GPR65, GPR27 HTT 3908/4885L3MBTL1 4494/4885MEN1 3600/4885
US-20110245227-A1 PYRIDONE GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS GPR119, GPR65, GPR27 HTT 3908/4885L3MBTL1 4494/4885MEN1 3600/4885
US-20090023702-A1 PYRIDONE GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS GPR119, GPR65, GPR27 HTT 3925/4885L3MBTL1 4498/4885MEN1 3664/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.